Coenzyme Q10, CoQ10
Coenzyme Q10 is a compound found in mitochondria that provides energy to the body’s cells and also plays an important role in the endogenous antioxidant system. It is similar to other pseudovitamin compounds, thus it is essential for survival. The body naturally produces this coenzyme, but its levels normally reduce with age. Coenzyme Q10 supplementation can improve the risks of cardiovascular disease, brain disorders, diabetes, cancer, and blood function, leading to reduced blood pressure.
- Origin: Synthetic, Nonessential
- Source: Milk, Eggs, Meat, Fish, Peanuts, Walnuts, Brazil Nuts, Pecan Nut, Almonds, Coconut, Hazelnut, Nonessential, Synthetic
- Type: Pseudovitamin
- Age Range: Adults (18-60), Seniors (>60)
- Toxicity: May be toxic in high doses
- Outcomes: Cardiovascular Health, Heart Protection
What are CoQ10 benefits?
Table of relations
Published articles about CoQ10 and Heart Protection
After oral ingestion of Glycine-Propionyl L-Carnitine, markers of lipid peroxidation were significantly reduced at 1g and 3g, although not significantly different between dosages. Nitric Oxide levels were increased with 3g, but did not change with 1g.
L-Carnitine Supplementation For Adults With End-stage Kidney Disease Requiring Maintenance Hemodialysis: A Systematic Review And Meta-analysis
When assessing all trials in persons on maintenance dialysis using supplementation of L-carnitine (any form) for a duration longer than two weeks, it was confirmed that there was a reduction in LDL cholesterol (not deemed clinically significant but reaching a mean reduction of −5.82mg/dL) and a reduction in C-reactive protein (clinically significant, a reduction of −3.65mg/L) although no other biomarker including those relating to erythropoietin dosage and hematocrit were affected. No adverse effects of L-carnitine supplementation were reported in any trial.
Levocarnitine Administration In Elderly Subjects With Rapid Muscle Fatigue: Effect On Body Composition, Lipid Profile And Fatigue
In elderly persons consuming 2g of L-carnitine daily over a period of 30 days was associated with improvements on blood lipid parameters (ApoE, ApoA, LDL-C, HDL-C) and body composition as well as less fatigue; both mental and physical.
Effect Of Oral L-carnitine Administration On Insulin Sensitivity And Lipid Profile In Type 2 Diabetes Mellitus Patients
12 type II diabetics were divided into two groups, in which one received 3g of L-Carnitine daily, in three doses of 1g with meals for 4 weeks. No significant changes were seen in basal lipid profile or insulin sensitivity.
In this randomized controlled trial, 230 individuals with acne underwent treatment with isotretinoin (Accutane) for 45 days. Of the 40 who developed myalgia (muscle pain) as a side effect, half received 100mg/kg L-Carnitine and half received a placebo every 24 hours.
L-Carnitine Supplementation Improved Clinical Status Without Changing Oxidative Stress And Lipid Profile In Women With Knee Osteoarthritis
In a randomized, double-blind, placebo-controlled trial, 72 participants with osteoarthritis took 750 mg of l-carnitine tartrate or placebo for 8 weeks. Malondialdehyde and total antioxidant capacity were reduced but the difference compared with placebo wasn't statistically significant. There weren't statistically significant differences for triglycerides, total cholesterol, HDL, LDL, weight, or body mass index.
Comparison Between Orlistat Plus L-carnitine And Orlistat Alone On Inflammation Parameters In Obese Diabetic Patients
In a randomized, double-blind, placebo-controlled trial, 258 participants with uncontrolled type 2 diabetes and obesity took 2 g of l-carnitine daily with or without orlistat for 1 year. There was a small but statistically significant greater reduction in body weight but not BMI in the carnitine group. HbA1c, fasting glucose, postprandial glucose, and insulin sensitivity were also improved statistically significantly more, while fasting insulin wasn't. LDL and total cholesterol but not HDL or triglycerides were improved significantly more. Adiponectin, but not TNF-a, vaspin, or hs-CRP, was improved significantly more, though the reduction was generally greater for carnitine.
Comparative Study To Evaluate The Effect Of L-carnitine Plus Glimepiride Versus Glimepiride Alone On Insulin Resistance In Type 2 Diabetic Patients
In a randomized, controlled trial 72 participants with type 2 diabetes took glimepiride alone or with 2 g of l-carnitine daily for 6 months. There was a statistically significant greater reduction in fasting glucose, postprandial glucose, glycated hemoglobin, fasting insulin, HOMA-IR, and increase in IRAPe in the carnitine group. TNF-A Visfatin, LDL, total cholesterol, triglycerides, and HDL all improved significantly more. There wasn't a statistically significant difference for BMI or blood pressure.
L-carnitine Ameliorated Fasting-induced Fatigue, Hunger, And Metabolic Abnormalities In Patients With Metabolic Syndrome: A Randomized Controlled Study
In this randomized, single-blind, placebo-controlled pilot trial, 30 participants with metabolic syndrome took for 7 days. The primary outcome was weight loss, and there was a statistically significant greater reduction in body mass and waist circumference, but not hip circumference. There was also a statistically significant reduction in total cholesterol, but not any other lipid measure. There was a statistically significant greater reduction in fasting insulin and GGT but not fasting glucose, insulin resistance, c-reactive protein, uric acid, free fatty acids, AST, or ALT, though many were close. The carnitine group perceived less hunger and reported less fatigue.
Carnitine supplementation improves metabolic flexibility and skeletal muscle acetylcarnitine formation in volunteers with impaired glucose tolerance: A randomised controlled trial
In a randomized, double-blind crossover trial, 12 healthy participants and 11 with impaired glucose tolerance took 2000 mg of l-carnitine tartrate for 36 days with a month of washout in between. Fasting glucose, insulin, HbA1c, liver enzymes, and lipid profile didn't show a statistically significant difference between groups for those with glucose tolerance. Metabolic flexibility during a high energy meal test was statistically significantly improved in the carnitine group.
Effects Of Combination Of Sibutramine And L-carnitine Compared With Sibutramine Monotherapy On Inflammatory Parameters In Diabetic Patients
In a randomized, double-blind, controlled trial, 254 participants with type 2 diabetes took sibutramine 10 mg or sibutramine with 2 g of l-carnitine daily for 12 months. There was statistically significantly more improvement in weight, HbA1c, fasting insulin, HOMA-IR, and adiponectin compared with the control group. The other outcomes (as seen in the values boxes) were not significantly different, but many showed a trend towards a difference.
Blood Pressure And Metabolic Effects Of Acetyl-l-Carnitine In Type 2 Diabetes: DIABASI Randomized Controlled Trial
In a randomized, double-blind, placebo-controled trial, 229 participants with hypertension and dyslipidemic type 2 diabetes took 1000 mg of acetyl-l-carnitine twice daily in addition to simvastatin, or only simvastatin for 6 months. The primary outcome was systolic blood pressure, and there wasn't an apparent benefit, nor for diastolic blood pressure, weight, HbA1c, insulin, insulin sensitivity, glucose disposal rate, lipid profile, or kidney function. There weren't notable differences in adverse events.
In a randomized, double-blind, controlled trial, 50 participants with hyperthyroidism took 2 or 4 g of carnitine daily for the first 4 months, placebo for the last 2 months, or 2 months of placebo followed by 2 months of carnitine, followed by 2 more months of placebo, while taking T4. There was also a control group that didn't receive carnitine. In both groups, all symptoms improved statistically significantly besides body weight; these include asthenia, dyspnea, palpitations, nervousness, insomnia, tremors, knee reflexes, and body weight. Asthenia improved significantly more in the group that received 2 months of 4 g of carnitine relative to 2 g, and there were no statistically significant differences in symptoms by dose for the other measures. Total cholesterol and urinary OH-P in the 2-month group and urinary OH-P in the 4-month group. Bone mineral density was improved by carnitine but the difference wasn't statistically significant compared with control.
L-carnitine Supplementation For The Management Of Fatigue In Patients With Hypothyroidism On Levothyroxine Treatment: A Randomized, Double-blind, Placebo-controlled Trial
In 12-week, randomized, double-blind, placebo-controlled trial, 60 participants with primary hypothyroidism who were taking levothyroxine took 1 g of l-carnitine daily or placebo. The primary outcome was fatigue, and there was a statistically significantly greater reduction in mental fatigue with carnitine, but a nonsignificant reduction with physical fatigue and fatigue severity index. When considered as a percentage who saw improvement, the carnitine group saw statistically significant improvements for all. Younger (less than 50) participants saw greater effects. There wasn't a statistically significant difference for body composition, fasting glucose, liver enzymes, HbA1c, lipid panel, or thyroid hormones. There weren't notable differences in adverse events.
The Effects Of Oral L-carnitine Treatment On Blood Lipid Metabolism And The Body Fat Content In The Diabetic Patient
In a randomized, double-blind trial, 46 participants with diabetes took 3 g of l-carnitine daily for 12 weeks. There was a greater reduction in body weight and BMI, but the difference wasn't statistically significant. There was a greater reduction in waist-hip ratio that was statistically significant compared with baseline, while the change wasn't for placebo. Carnitine performed better for fasting glucose and HbA1c but nonsignificantly. Triglycerides were reduced statistically significantly more in the carnitine group whereas total cholesterol, Apo-A1, Apo-B (g/L), and HDL, HDL2, and HDL 3 weren't statistically significant. The weight loss for the carnitine group came more from trunk fat than any of the limbs.
Plasma Trimethylamine-N-oxide Following Cessation Of L-carnitine Supplementation In Healthy Aged Women
Eighteen female participants visited the laboratory after 24 weeks of taking 1500 mg of L-carnitine-L-tartrate or isonitrogenous placebo per day. They returned 4 and 12 months after cessation of supplementation for more testing. The carnitine group saw substantially higher TMAO concentrations by the end of supplementation, which reverted to the placebo levels after 4 months. There weren't statistically significant differences for blood lipids, though. Levels of immune cells weren't statistically significantly different.
Evaluation of L-Carnitine Efficacy in the Treatment of Non-Alcoholic Fatty Liver Disease among Diabetic Patients: A Randomized Double Blind Pilot Study
In a randomized, double-blind pilot study, 60 type 2 diabetes patients with NAFLD took for 750 mg of l-carnitine 3 times daily for 6 months or placebo. AST and ALT shows a statistically significantly greater improvement for the carnitine group, while cholesterol, triglycerides, and HbA1c didn't.
Effect Of Carnitine-orotate Complex On Glucose Metabolism And Fatty Liver: A Double-blind, Placebo-controlled Study
In a randomized, double-blind, placebo-controlled trial, 52 participants with impaired glucose tolerance and fatty liver took 900 mg of l-carnitine in combination with metformin or placebo in combination with metformin daily for 12 weeks. ALT was the primary outcome, and there was a statistically significantly greater reduction in the carnitine group, but not for AST or ALP. The reduction in hs-CRP and 8-OHdG were also statistically significant, though lipid profile, metabolic markers, blood pressure, and everything else wasn't.
Oral Carnitine Supplementation Reduces Body Weight And Insulin Resistance In Women With Polycystic Ovary Syndrome: A Randomized, Double-blind, Placebo-controlled Trial
This randomized, double-blind, placebo-controlled trial investigated the effectiveness of L-carnitine on weight loss, and glycaemic and lipid profiles in females with polycystic ovary syndrome (PCOS). For 12 weeks, the intervention group (n = 30) took 250 mg/day L-carnitine while the control group (n = 30) took a placebo. At the studies end, the L-carnitine saw small to moderate improvements in weight, BMI, WC, HC, and glycaemic control. It did not affect lipid profiles or free testosterone.
Efficacy And Tolerability Of Combined Treatment With L-carnitine And Simvastatin In Lowering Lipoprotein(a) Serum Levels In Patients With Type 2 Diabetes Mellitus
In a randomized, open-label trial, 52 participants with type 2 diabetes and high Lp(A) levels took simvastatin alone or with 2 g of L-carnitine for 60 days. There was a statistically significant greater reduction in lipoprotein A in the combination group, though no superior for the rest of the lipid profile, including total cholesterol, LDL, HDL, non-HDL, triglycerides, and apolipoprotein B.
Effect Of L-carnitine On Plasma Glycemic And Lipidemic Profile In Patients With Type II Diabetes Mellitus
In a randomized, double-blind, placebo-controlled trial, 35 participants with type 2 diabetes who were taking anti-diabetic drugs took a placebo or 3 g of L-carnitine daily divided into 3 doses, one at each meal, for 12 weeks. There was a statistically significantly greater reduction in fasting glucose and an increase in triglycerides and Apo B and Apo A-I in the carnitine group. There wasn't a statistically significant difference for HbA1c, total cholesterol, HDL, LDL, or Lp(a).
Effects Of Simvastatin And Carnitine Versus Simvastatin On Lipoprotein(a) And Apoprotein(a) In Type 2 Diabetes Mellitus
In a randomized, double-blind, placebo-controlled trial, 75 participants with type 2 diabetes took simvastatin with or without 2 g of carnitine daily for 4 months. There was a statistically significantly greater reduction in blood glucose, triglycerides, ApoA1, LP(a), and Apo(a), and an increase in HDL. There wasn't a statistically significant difference in BMI or HbA1c.
In a randomized, controlled trial, 81 participants with type 2 diabetes took 2 g of L-carnitine daily or placebo in combination with seeing a dietician and consuming a low-fat weight-loss diet for 3 months. The primary outcome was change in lipid profile, and the carnitine group saw a greater, statistically significant improvement in total cholesterol, LDL, HDL, triglycerides, and Apolipoprotein B-100, and an increase in Apolipoprotein A1. There was a greater, statistically significant reduction in oxidized LDL cholesterol in the carnitine group, as well as a general reduction in oxidative stress.
Effect Of Lysine, Vitamin B(6), And Carnitine Supplementation On The Lipid Profile Of Male Patients With Hypertriglyceridemia: A 12-week, Open-label, Randomized, Placebo-controlled Trial
In a randomized, open-label, placebo-controlled trial, 40 participants with hypertriglyceridemia took 1 g of carnitine, placebo, or various other supplements (which won't be mentioned, for our purposes, the relevant comparison is carnitine vs. placebo) for 12 weeks. There wasn't a statistically significant difference for change in weight, triglycerides, total cholesterol, HDL, LDL, and fasting glucose.
In a randomized, single-blind, placebo-controlled trial, 47 CAD patients took 1 g of L-carnitine or placebo daily for 12 weeks. There was statistically significantly greater superoxide dismutase activity, HDL, and APO-A1 in the carnitine group, though it's unclear if this was due to differences at baseline. There weren't statistically significant differences for total cholesterol, triglycerides, LDL or Apo-B.
Effects Of Combined Treatment With Simvastatin And L-carnitine On Triglyceride Levels In Diabetic Patients With Hyperlipidaemia
In a randomized, open-label trial, 32 patients with type 2 diabetes and abnormal lipid concentrations took 4 g of L-carnitine or placebo with simvastatin daily for 2 months. There was a statistically significant greater reduction in triglycerides in the carnitine group. There was a nonsignificant greater increase in HDL and reduction in total cholesterol.
L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared With Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study
In a randomized, double-blind, placebo-controlled trial 58 participants with hyperlipidemia took 2 g of L-carnitine daily with simvastatin or just simvastatin for 12 weeks. Participants followed a low-calorie weight loss diet. The primary outcome was the change in Lp(a), and there was a statistically significantly greater reduction in the carnitine group. There weren't statistically significant or meaningful differences for total cholesterol, triglycerides, HDL, LDL, Apolipoprotein A-1, or Apolipoprotein B.
Efficacy Of L-carnitine Supplementation For Management Of Blood Lipids: A Systematic Review And Dose-response Meta-analysis Of Randomized Controlled Trials
This was a meta-analysis of randomized controlled trials investigating the impact of carnitine supplements on lipid profile. In total, 55 trials were included. There was a statistically significant reduction in total cholesterol, LDL, and triglycerides when taking carnitine. There was a small, statistically significant increase in HDL.
Effect of carnitine supplementation on progression of carotid plaque in the metabolic syndrome: the ECoM study
In a randomized, double-blind, placebo-controlled trial, 177 participants with metabolic syndrome took 2 g of L-carnitine or placebo daily for 6 months. There wasn't a statistically significant difference for total plaque volume, but plaque stenosis increased significantly more in the carnitine group than the placebo group. Total and LDL cholesterol were higher in the L-carnitine group.
The Effect Of L-carnitine On Plasma Lipoprotein(a) Levels In Hypercholesterolemic Patients With Type 2 Diabetes Mellitus
In a randomized, double-blind, placebo-controlled trial, 94 participants with hypercholesterolemia and type 2 diabetes took 2 g of L-carnitine or placebo daily for 6 months. There was a statistically significant greater reduction in lipoprotein A in the carnitine group. There weren't statistically significant differences between groups for BMI, fasting glucose, postprandial glucose, HbA1c, fasting insulin, total cholesterol, LDL, HDL, triglycerides, Apo A-1, or Apo B.
L-Carnitine's Effect On The Biomarkers Of Metabolic Syndrome: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials
This was a meta-analysis of randomized, controlled trials investigating the effects of l-carnitine for at least two weeks on metabolic syndrome outcomes, including waist circumference, blood pressure, fasting glucose, triglycerides, and HDL. The studies had to be without the use of other drugs. It included 9 trials that included 508 participants. Doses ranged from 0.75 to 3 g per day and 2 g was the most common dose. The studies weren't generally at a high risk of bias, but none stood out as particularly rigorous. Based on two studies, there was a statistically significant reduction in waist circumference and systolic but not quite diastolic blood pressure. There was a statistically reduction in fasting glucose, triglycerides, and anHDL increase based on 5-6 studies, though the differences weren't statistically significant. The subgroup analysis found greater effects for more severe metabolic syndrome and greater effects for higher carnitine doses, but the comparisons were based on few studies.
Effects Of Coenzyme Q10 Supplementation On Liver Mitochondrial Function And Aerobic Capacity In Adolescent Athletes
After supplementation of 100mg CoQ10 daily, serum levels of CoQ10 were increased while they were decreased in the placebo group due to exercise. Normalized oxidation rates were seen with CoQ10 while increases in oxidation and lipid peroxidation were seen in placebo. Despite the above beneficial trends, no significant effects on exercise performance were noted.
In a randomized, double-blind, crossover trial, 15 exercise-trained participants took 300 mg of ubiquinol daily and placebo for four weeks, separated by a 3-week washout period. Participants maintained their exercise routines and were subjected to graded exercise tests on treadmills and cycle sprint tests on a cycle ergometer. There were no statistically significant differences in heart rate, perceived exertion, or time on the treadmill test, and no statistically significant differences in heart rate, perceived exertion, peak power, mean power, or total work on the cycling test. There were no statistically significant differences in malondialdehyde, hydrogen peroxide, or total cholesterol at rest, nor were there statistically significant differences in malondialdehyde, hydrogen peroxide, or lactate during the exercise tests.
In persons with chronic heart failure, CoQ10 at 300mg daily (in three divided dosages) was able to increase functional capacity and endothelial function after 4 weeks of supplementation. Benefits of CoQ10 on one of the parameters of heart health (systolic wall thickening index) was synergistic with exercise.
Effect Of Coenzyme Q10 Administration On Endothelial Function And Extracellular Superoxide Dismutase In Patients With Ischaemic Heart Disease: A Double-blind, Randomized Controlled Study
CoQ10 was shown to increase endothelial function secondary to extracellular Superoxide dismustase activity, and was hypothesized to negate adverse effects of nitric oxide oxidation. Improvements in VO(2) max were seen in this population of persons with ischaemic heart disease at 100mg daily.
D-Ribose Improves Diastolic Function And Quality Of Life In Congestive Heart Failure Patients: A Prospective Feasibility Study
This study used an exhaustive week-long exercise protocol (two sessions of cycling daily) where after the last session, as well as nine times more over the next three days, either the experimental group (200mg/kg D-ribose paired with 200mg/kg sucrose at each dose) or control group (200mg/kg maltodextrin replacing the D-ribose) were assessed after three days rest. Inclusion of D-ribose was associated with a greater rate of ATP replenishment in the tested muscle after three days when compared to placebo, and no difference between groups was noted after a single day of rest. No differences in glycogen resynthesis rates between D-ribose and maltodextrin. This was a crossover study.
At 0.125g/kg bodyweight, glutamine supplementation did not influence exercise capacity or markers of oxidative metabolism in person with COPD.
Supplementation of 80mg/kg glutamine in persons with chronic stable angina was associated with improved endurance and performance on a Bruce test when taken 40 minutes prior; this occurred alongside a plasma increase in glutamine.
Pycnogenol, French Maritime Pine Bark Extract, Augments Endothelium-dependent Vasodilation In Humans
180mg of Pycnogenol for 2 weeks in otherwise healthy adult men was able to increase the acetylcholine-induced relaxation response in blood vessels, secondary to nitric oxide
Effects Of Pycnogenol On Endothelial Function In Patients With Stable Coronary Artery Disease: A Double-blind, Randomized, Placebo-controlled, Cross-over Study
In persons with Coronary Artery Disease, Pycnogenol at 200mg daily for 8 weeks is associated with an improvement of blood flow independent of changes in blood pressure
Pycnogenol, French Maritime Pine Bark Extract, Improves Endothelial Function Of Hypertensive Patients
A double-blind, placebo controlled study of 58 patients with hypertension evaluated the ability of pycnogenol (100 mg/ day over 12 weeks) to reduce the required dose of the anti-hypertensive medication nifedipine. The study found that subjects in the pycnogenol group were able to reduce the dose of nifedipine required to restore blood pressure levels to normal. While the placebo group required on average 21.5 mg of nifedipine to remain normotensive, the pycnogenol group required only 15 mg, a reduction of 6.5 mg.[PMID: 14659974]. The effects of pycnogenol alone on blood pressure were not evaluated in this study (since all patients remained on their current meds). Pycnogenol supplementation was also associated with improved blood flow and trended towards higher NO levels in serum. The evidence does suggest that pycnogenol has a modest blood pressure lowering effect that may complement the effects of other anti-hypertensive medications.
The heart is one of the most strong muscles in the body, as it works nonstop and very steady. But it can also fail, brought down by a poor diet and lack of exercise, smoking, infection, unlucky genes, etc. It's essential to your health to take care of your heart health.
Table of negative interactions
Related videos about CoQ10
- ^ a b Felippi CC, et al. Safety and efficacy of antioxidants-loaded nanoparticles for an anti-aging application. J Biomed Nanotechnol. (2012)
- ^ a b Trimarco V, et al. Nutraceuticals for blood pressure control in patients with high-normal or grade 1 hypertension. High Blood Press Cardiovasc Prev. (2012)
- ^ a b Folkers K. Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun. (1996)
- ^ a b c Yuan Y, Tian Y, Yue T. Improvement of coenzyme Q10 production: mutagenesis induced by high hydrostatic pressure treatment and optimization of fermentation conditions. J Biomed Biotechnol. (2012)
- ^ a b c d e f g h i j k Coenzymes Q9 and Q10: Contents in Foods and Dietary Intake.
- ^ a b c d e f g h i j k l m n o p q r Food content of ubiquinol-10 and ubiquinone-10 in the Japanese diet.
- ^ a b c d e f The Quality Control Assessment of Commercially Available Coenzyme Q10-Containing Dietary and Health Supplements in Japan.
- ^ a b c d e f g h i j k Pravst I, Zmitek K, Zmitek J. Coenzyme Q10 contents in foods and fortification strategies. Crit Rev Food Sci Nutr. (2010)
- ^ Importance and presence of several bio quinones in foods.
- ^ a b c d e f g Kamei M, et al. The distribution and content of ubiquinone in foods. Int J Vitam Nutr Res. (1986)
- ^ a b c d e f g h i j Passi S, et al. Fatty acid composition and antioxidant levels in muscle tissue of different Mediterranean marine species of fish and shellfish. J Agric Food Chem. (2002)
- ^ a b c d e Seasonal variation of Co-enzyme Q10 content in pelagic fish tissues from Eastern Quebec.
- ^ a b Weber C, Bysted A, Hølmer G. Coenzyme Q10 in the diet–daily intake and relative bioavailability. Mol Aspects Med. (1997)
- ^ Comparison of in-line connected diode array and electrochemical detectors in the high-performance liquid chromatographic analysis of coenzymes Q9 and Q10 in food materials.
- ^ a b Strazisar M, et al. Quantitative determination of coenyzme Q10 by liquid chromatography and liquid chromatography/mass spectrometry in dairy products. J AOAC Int. (2005)
- ^ a b Weber C, Bysted A, Hłlmer G. The coenzyme Q10 content of the average Danish diet. Int J Vitam Nutr Res. (1997)
- ^ Comparison of low-temperature processes for oil and coenzyme Q10 extraction from mackerel and herring.
- ^ a b Yoshida H, et al. Production of ubiquinone-10 using bacteria. J Gen Appl Microbiol. (1998)
- ^ Total synthesis of polyprenoid natural-products via pd(o)-catalyzed oligomerizations.
- ^ Cluis CP, Burja AM, Martin VJ. Current prospects for the production of coenzyme Q10 in microbes. Trends Biotechnol. (2007)
- ^ Choi JH, Ryu YW, Seo JH. Biotechnological production and applications of coenzyme Q10. Appl Microbiol Biotechnol. (2005)
- ^ Ha SJ, et al. Optimization of culture conditions and scale-up to pilot and plant scales for coenzyme Q10 production by Agrobacterium tumefaciens. Appl Microbiol Biotechnol. (2007)
- ^ Lactate increases coenzyme Q10 production by Agrobacterium tumefaciens.
- ^ Zhang D, et al. Ubiquinone-10 production using Agrobacterium tumefaciens dps gene in Escherichia coli by coexpression system. Mol Biotechnol. (2007)
- ^ a b c d e f g Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. (2006)
- ^ UBIQUINONE-10 AS AN ANTIOXIDANT.
- ^ Nohl H, Gille L, Staniek K. The biochemical, pathophysiological, and medical aspects of ubiquinone function. Ann N Y Acad Sci. (1998)
- ^ Mancuso M, et al. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets. (2010)
- ^ Beg S, Javed S, Kohli K. Bioavailability enhancement of coenzyme Q10: an extensive review of patents. Recent Pat Drug Deliv Formul. (2010)
- ^ The Biosynthesis of Ubiquinone and Rhodoquinone from p-Hydroxybenzoate and D-Hydroxybenzaldehyde in Rhodospirillum rubrum.
- ^ Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. (1990)
- ^ Bentinger M, Tekle M, Dallner G. Coenzyme Q–biosynthesis and functions. Biochem Biophys Res Commun. (2010)
- ^ Thelin A, et al. Effect of squalestatin 1 on the biosynthesis of the mevalonate pathway lipids. Biochim Biophys Acta. (1994)
- ^ Keller RK. Squalene synthase inhibition alters metabolism of nonsterols in rat liver. Biochim Biophys Acta. (1996)
- ^ Biochemical and clinical consequences of inhibiting coenzyme Q10 biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): A critical overview.
- ^ Kalén A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tissues. Lipids. (1989)
- ^ a b Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. (1995)
- ^ Bonakdar RA, Guarneri E. Coenzyme Q10. Am Fam Physician. (2005)
- ^ COENZYME Q-10: EFFICACY, SAFETY, AND USE.
- ^ a b c Zhang Y, et al. Uptake of dietary coenzyme Q supplement is limited in rats. J Nutr. (1995)
- ^ Distribution of Coenzyme Q in Rat Liver Cell Fractions.
- ^ a b c d e Zhang Y, Turunen M, Appelkvist EL. Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of alpha-tocopherol into rat organs and cells. J Nutr. (1996)
- ^ Saito Y, et al. Characterization of cellular uptake and distribution of coenzyme Q10 and vitamin E in PC12 cells. J Nutr Biochem. (2009)
- ^ Dietary antioxidants: potential effects on oxidative products in cigarette smoke.
- ^ Studies on lymphatic absorption of 1′,2′-( 3 H)-coenzyme Q 10 in rats.
- ^ Assessment of coenzyme Q10 absorption using an in vitro digestion-Caco-2 cell model.
- ^ a b Bentinger M, et al. Distribution and breakdown of labeled coenzyme Q10 in rat. Free Radic Biol Med. (2003)
- ^ Bioequivalence of coenzyme Q10 from over-the-counter supplements.
- ^ a b Miles MV, et al. Plasma coenzyme Q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults. Clin Chim Acta. (2003)
- ^ Lönnrot K, et al. The effect of ascorbate and ubiquinone supplementation on plasma and CSF total antioxidant capacity. Free Radic Biol Med. (1996)
- ^ a b Lyon W, et al. Similar therapeutic serum levels attained with emulsified and oil-based preparations of coenzyme Q10. Asia Pac J Clin Nutr. (2001)
- ^ a b c Chopra RK, et al. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam Nutr Res. (1998)
- ^ Weber C, et al. Antioxidative effect of dietary coenzyme Q10 in human blood plasma. Int J Vitam Nutr Res. (1994)
- ^ Folkers K, Moesgaard S, Morita M. A one year bioavailability study of coenzyme Q10 with 3 months withdrawal period. Mol Aspects Med. (1994)
- ^ a b c Kaikkonen J, et al. Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL+LDL fraction: absorption and antioxidative properties of oil and granule-based preparations. Free Radic Biol Med. (1997)
- ^ a b Lu WL, et al. Total coenzyme Q10 concentrations in Asian men following multiple oral 50-mg doses administered as coenzyme Q10 sustained release tablets or regular tablets. Biol Pharm Bull. (2003)
- ^ a b Nuku K, et al. Safety assessment of PureSorb-Q40 in healthy subjects and serum coenzyme Q10 level in excessive dosing. J Nutr Sci Vitaminol (Tokyo). (2007)
- ^ Nukui K, et al. Comparison of uptake between PureSorb-Q40 and regular hydrophobic coenzyme Q10 in rats and humans after single oral intake. J Nutr Sci Vitaminol (Tokyo). (2007)
- ^ Nukui K, et al. A 91-d repeated dose oral toxicity study of PureSorb-Q(TM)40 in rats. J Nutr Sci Vitaminol (Tokyo). (2007)
- ^ Laaksonen R, et al. Serum and muscle tissue ubiquinone levels in healthy subjects. J Lab Clin Med. (1995)
- ^ a b c d Aberg F, et al. Distribution and redox state of ubiquinones in rat and human tissues. Arch Biochem Biophys. (1992)
- ^ Bioequivalence of coenzyme Q10 from over-the-counter supplements.
- ^ Sohal RS, Forster MJ. Coenzyme Q, oxidative stress and aging. Mitochondrion. (2007)
- ^ Lass A, Forster MJ, Sohal RS. Effects of coenzyme Q10 and alpha-tocopherol administration on their tissue levels in the mouse: elevation of mitochondrial alpha-tocopherol by coenzyme Q10. Free Radic Biol Med. (1999)
- ^ a b c Matthews RT, et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. (1998)
- ^ Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effect.
- ^ Kwong LK, et al. Effects of coenzyme Q(10) administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Radic Biol Med. (2002)
- ^ Kamzalov S, et al. Coenzyme Q intake elevates the mitochondrial and tissue levels of Coenzyme Q and alpha-tocopherol in young mice. J Nutr. (2003)
- ^ Niklowitz P, et al. Enrichment of coenzyme Q10 in plasma and blood cells: defense against oxidative damage. Int J Biol Sci. (2007)
- ^ a b c Baskaran R1, et al. The effect of coenzyme Q10 on the pharmacokinetic parameters of theophylline. Arch Pharm Res. (2008)
- ^ a b Itagaki S1, et al. Interaction of coenzyme Q10 with the intestinal drug transporter P-glycoprotein. J Agric Food Chem. (2008)
- ^ Zhou Q1, Zhou S, Chan E. Effect of coenzyme Q10 on warfarin hydroxylation in rat and human liver microsomes. Curr Drug Metab. (2005)
- ^ Zhou S1, Chan E. Effect of ubidecarenone on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats. Drug Metabol Drug Interact. (2001)
- ^ [Interaction between warfarin and coenzyme Q10.
- ^ a b Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet. (1994)
- ^ Shalansky S1, et al. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy. (2007)
- ^ Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost. (2002)
- ^ a b Parrado-Fernández C, et al. Calorie restriction modifies ubiquinone and COQ transcript levels in mouse tissues. Free Radic Biol Med. (2011)
- ^ Lass A, Kwong L, Sohal RS. Mitochondrial coenzyme Q content and aging. Biofactors. (1999)
- ^ Ramsey JJ, et al. Proton leak and hydrogen peroxide production in liver mitochondria from energy-restricted rats. Am J Physiol Endocrinol Metab. (2004)
- ^ Kamzalov S, Sohal RS. Effect of age and caloric restriction on coenzyme Q and alpha-tocopherol levels in the rat. Exp Gerontol. (2004)
- ^ Armeni T, et al. Mitochondrial dysfunctions during aging: vitamin E deficiency or caloric restriction–two different ways of modulating stress. J Bioenerg Biomembr. (2003)
- ^ Spindler SR, et al. Statin treatment increases lifespan and improves cardiac health in Drosophila by decreasing specific protein prenylation. PLoS One. (2012)
- ^ Larsen PL, Clarke CF. Extension of life-span in Caenorhabditis elegans by a diet lacking coenzyme Q. Science. (2002)
- ^ Asencio C, et al. Silencing of ubiquinone biosynthesis genes extends life span in Caenorhabditis elegans. FASEB J. (2003)
- ^ Branicky R, Bénard C, Hekimi S. clk-1, mitochondria, and physiological rates. Bioessays. (2000)
- ^ Saiki R, et al. Altered bacterial metabolism, not coenzyme Q content, is responsible for the lifespan extension in Caenorhabditis elegans fed an Escherichia coli diet lacking coenzyme Q. Aging Cell. (2008)
- ^ a b c Sohal RS, et al. Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice. Free Radic Biol Med. (2006)
- ^ a b Lönnrot K, et al. The effects of lifelong ubiquinone Q10 supplementation on the Q9 and Q10 tissue concentrations and life span of male rats and mice. Biochem Mol Biol Int. (1998)
- ^ Lee CK, et al. The impact of alpha-lipoic acid, coenzyme Q10 and caloric restriction on life span and gene expression patterns in mice. Free Radic Biol Med. (2004)
- ^ a b c d e f Sumien N, et al. Prolonged intake of coenzyme Q10 impairs cognitive functions in mice. J Nutr. (2009)
- ^ Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.
- ^ Shetty RA, Forster MJ, Sumien N. Coenzyme Q(10) supplementation reverses age-related impairments in spatial learning and lowers protein oxidation. Age (Dordr). (2012)
- ^ Fornai F, et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A. (2005)
- ^ a b c d Yang L, et al. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s diseases. J Neurochem. (2009)
- ^ The Mitochondrial Toxin 3-Nitropropionic Acid Induces Striatal Neurodegeneration via a c-Jun N-Terminal Kinase/c-Jun Module.
- ^ Schulz JB, et al. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience. (1996)
- ^ a b Virmani A, Gaetani F, Binienda Z. Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: metabolic inhibitors, MPTP, and methamphetamine. Ann N Y Acad Sci. (2005)
- ^ a b c Beal MF. Neuroprotective effects of creatine. Amino Acids. (2011)
- ^ Maes M, et al. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry. (2011)
- ^ a b c Maes M, et al. Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett. (2009)
- ^ a b Aboul-Fotouh S. Coenzyme Q10 displays antidepressant-like activity with reduction of hippocampal oxidative/nitrosative DNA damage in chronically stressed rats. Pharmacol Biochem Behav. (2013)
- ^ Forester BP, et al. Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. J Geriatr Psychiatry Neurol. (2012)
- ^ a b Rozen TD, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia. (2002)
- ^ a b Sándor PS, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. (2005)
- ^ a b Slater SK, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. (2011)
- ^ Rosenfeldt F, et al. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac Cardiovasc Surg. (2005)
- ^ a b Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A. (1985)
- ^ Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci U S A. (1985)
- ^ Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther. (2005)
- ^ Greenlee H, et al. Lack of effect of coenzyme q10 on doxorubicin cytotoxicity in breast cancer cell cultures. Integr Cancer Ther. (2012)
- ^ Zhou Q, Chowbay B. Effect of coenzyme Q10 on the disposition of doxorubicin in rats. Eur J Drug Metab Pharmacokinet. (2002)
- ^ El-Sheikh AA, et al. Effect of coenzyme-q10 on Doxorubicin-induced nephrotoxicity in rats. Adv Pharmacol Sci. (2012)
- ^ Shinozawa S, Gomita Y, Araki Y. Protective effects of various drugs on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice and rats. Biol Pharm Bull. (1993)
- ^ Eaton S, et al. Plasma coenzyme Q(10) in children and adolescents undergoing doxorubicin therapy. Clin Chim Acta. (2000)
- ^ Brea-Calvo G, et al. Chemotherapy induces an increase in coenzyme Q10 levels in cancer cell lines. Free Radic Biol Med. (2006)
- ^ a b Molyneux SL, et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. (2008)
- ^ Hughes K, et al. Coenzyme Q10 and differences in coronary heart disease risk in Asian Indians and Chinese. Free Radic Biol Med. (2002)
- ^ Kalenikova EI, et al. Chronic administration of coenzyme Q10 limits postinfarct myocardial remodeling in rats. Biochemistry (Mosc). (2007)
- ^ Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Curr Opin Clin Nutr Metab Care. (2005)
- ^ Sarter B. Coenzyme Q10 and cardiovascular disease: a review. J Cardiovasc Nurs. (2002)
- ^ a b Singh RB, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther. (1998)
- ^ a b c Singh RB, et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem. (2003)
- ^ Khatta M, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. (2000)
- ^ Chew GT, et al. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care. (2008)
- ^ Permanetter B, et al. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J. (1992)
- ^ Hofman-Bang C, et al. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. J Card Fail. (1995)
- ^ Adarsh K, Kaur H, Mohan V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors. (2008)
- ^ Alehagen U, et al. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: A 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol. (2013)
- ^ a b Tiano L, et al. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Heart J. (2007)
- ^ Marklund SL. Extracellular superoxide dismutase and other superoxide dismutase isoenzymes in tissues from nine mammalian species. Biochem J. (1984)
- ^ Landmesser U, et al. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. (2000)
- ^ Hare JM, Stamler JS. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest. (2005)
- ^ Fukai T, et al. Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc Res. (2002)
- ^ a b Hamilton SJ, Chew GT, Watts GF. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care. (2009)
- ^ Watts GF, et al. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia. (2002)
- ^ Belardinelli R, et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J. (2006)
- ^ a b Lee YJ, et al. Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study. J Med Food. (2011)
- ^ Gao L, et al. Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials. Atherosclerosis. (2012)
- ^ a b Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. (2009)
- ^ Young JM, et al. A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. Am J Hypertens. (2012)
- ^ a b c Mabuchi H, et al. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis. (2007)
- ^ Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol.
- ^ Yamashita S, Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal Biochem. (1997)
- ^ Yamamoto Y, Yamashita S. Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Mol Aspects Med. (1997)
- ^ Tomasetti M, et al. Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. Biofactors. (1999)
- ^ a b Tsai KL, et al. A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathways. J Nutr Biochem. (2012)
- ^ a b c d Tsai KL, et al. Coenzyme Q10 suppresses oxLDL-induced endothelial oxidative injuries by the modulation of LOX-1-mediated ROS generation via the AMPK/PKC/NADPH oxidase signaling pathway. Mol Nutr Food Res. (2011)
- ^ Marshall HE, Merchant K, Stamler JS. Nitrosation and oxidation in the regulation of gene expression. FASEB J. (2000)
- ^ Schmelzer C, et al. Functions of coenzyme Q10 in inflammation and gene expression. Biofactors. (2008)
- ^ Lee BJ, et al. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease. Nutrition. (2012)
- ^ Singh RB, et al. Plasma levels of antioxidant vitamins and oxidative stress in patients with acute myocardial infarction. Acta Cardiol. (1994)
- ^ a b Mezawa M, et al. The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study. Biofactors. (2012)
- ^ McCarty MF. Can correction of sub-optimal coenzyme Q status improve beta-cell function in type II diabetics. Med Hypotheses. (1999)
- ^ Hodgson JM, et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. (2002)
- ^ Dzugkoev SG, Kaloeva MB, Dzugkoeva FS. Effect of combination therapy with coenzyme Q10 on functional and metabolic parameters in patients with type 1 diabetes mellitus. Bull Exp Biol Med. (2012)
- ^ Eriksson JG, et al. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors. (1999)
- ^ Golbidi S, Ebadi SA, Laher I. Antioxidants in the treatment of diabetes. Curr Diabetes Rev. (2011)
- ^ Kostolanská J, Jakus V, Barák L. HbA1c and serum levels of advanced glycation and oxidation protein products in poorly and well controlled children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. (2009)
- ^ Persson MF, et al. Coenzyme Q10 prevents GDP-sensitive mitochondrial uncoupling, glomerular hyperfiltration and proteinuria in kidneys from db/db mice as a model of type 2 diabetes. Diabetologia. (2012)
- ^ Sourris KC, et al. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med. (2012)
- ^ Ahmadvand H, Tavafi M, Khosrowbeygi A. Amelioration of altered antioxidant enzymes activity and glomerulosclerosis by coenzyme Q10 in alloxan-induced diabetic rats. J Diabetes Complications. (2012)
- ^ Huynh K, et al. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia. (2012)
- ^ Shi TJ, et al. Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes model. Proc Natl Acad Sci U S A. (2013)
- ^ Zhang YP, et al. Prophylactic and Antinociceptive Effects of Coenzyme Q10 on Diabetic Neuropathic Pain in a Mouse Model of Type 1 Diabetes. Anesthesiology. (2013)
- ^ a b c Duncan AJ, et al. Determination of coenzyme Q10 status in blood mononuclear cells, skeletal muscle, and plasma by HPLC with di-propoxy-coenzyme Q10 as an internal standard. Clin Chem. (2005)
- ^ Miles MV, et al. Age-related changes in plasma coenzyme Q10 concentrations and redox state in apparently healthy children and adults. Clin Chim Acta. (2004)
- ^ a b Karlsson J, et al. Muscle ubiquinone in healthy physically active males. Mol Cell Biochem. (1996)
- ^ a b c Wagner AE, et al. A combination of lipoic acid plus coenzyme Q10 induces PGC1α, a master switch of energy metabolism, improves stress response, and increases cellular glutathione levels in cultured C2C12 skeletal muscle cells. Oxid Med Cell Longev. (2012)
- ^ Lin J, et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature. (2002)
- ^ Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. (2006)
- ^ Anderson R, Prolla T. PGC-1alpha in aging and anti-aging interventions. Biochim Biophys Acta. (2009)
- ^ Pilegaard H, Saltin B, Neufer PD. Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle. J Physiol. (2003)
- ^ Nierobisz LS, et al. Fiber phenotype and coenzyme Q₁₀ content in Turkey skeletal muscles. Cells Tissues Organs. (2010)
- ^ Sommerville RB, Zaidman CM, Pestronk A. Coenzyme Q10 deficiency in children: Frequent type 2C muscle fibers with normal morphology. Muscle Nerve. (2013)
- ^ a b Deichmann RE, Lavie CJ, Dornelles AC. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins. Phys Sportsmed. (2012)
- ^ a b Cooke M, et al. Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals. J Int Soc Sports Nutr. (2008)
- ^ a b Ostman B, et al. Coenzyme Q10 supplementation and exercise-induced oxidative stress in humans. Nutrition. (2012)
- ^ Bloomer RJ, et al. Impact of oral ubiquinol on blood oxidative stress and exercise performance. Oxid Med Cell Longev. (2012)
- ^ Zhou S, et al. Muscle and plasma coenzyme Q10 concentration, aerobic power and exercise economy of healthy men in response to four weeks of supplementation. J Sports Med Phys Fitness. (2005)
- ^ a b c Gökbel H, et al. The effects of coenzyme Q10 supplementation on performance during repeated bouts of supramaximal exercise in sedentary men. J Strength Cond Res. (2010)
- ^ Gül I, et al. Oxidative stress and antioxidant defense in plasma after repeated bouts of supramaximal exercise: the effect of coenzyme Q10. J Sports Med Phys Fitness. (2011)
- ^ Muraki A, et al. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. J Appl Physiol. (2012)
- ^ a b Mizuno K, et al. Antifatigue effects of coenzyme Q10 during physical fatigue. Nutrition. (2008)
- ^ Kon M, et al. Effect of Coenzyme Q10 supplementation on exercise-induced muscular injury of rats. Exerc Immunol Rev. (2007)
- ^ Nagai S, et al. The effect of Coenzyme Q10 on reperfusion injury in canine myocardium. J Mol Cell Cardiol. (1985)
- ^ Kambara N, et al. Mechanism responsible for endotoxin-induced lung microsomal dysfunction in rats. Lung. (1983)
- ^ Kon M, et al. Reducing exercise-induced muscular injury in kendo athletes with supplementation of coenzyme Q10. Br J Nutr. (2008)
- ^ Zheng A, Moritani T. Influence of CoQ10 on autonomic nervous activity and energy metabolism during exercise in healthy subjects. J Nutr Sci Vitaminol (Tokyo). (2008)
- ^ Fu X, Ji R, Dam J. Antifatigue effect of coenzyme Q10 in mice. J Med Food. (2010)
- ^ Sun M, et al. Mitochondrial nutrients stimulate performance and mitochondrial biogenesis in exhaustively exercised rats. Scand J Med Sci Sports. (2012)
- ^ Glover EI, et al. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve. (2010)
- ^ Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr. (2001)
- ^ Linnane AW, et al. Cellular redox activity of coenzyme Q10: effect of CoQ10 supplementation on human skeletal muscle. Free Radic Res. (2002)
- ^ Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta. (2004)
- ^ a b Bentinger M, Brismar K, Dallner G. The antioxidant role of coenzyme Q. Mitochondrion. (2007)
- ^ Forsmark-Andrée P, et al. Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles. Free Radic Biol Med. (1997)
- ^ a b Mukai K, Kikuchi S, Urano S. Stopped-flow kinetic study of the regeneration reaction of tocopheroxyl radical by reduced ubiquinone-10 in solution. Biochim Biophys Acta. (1990)
- ^ Forsmark-Andrée P, Dallner G, Ernster L. Endogenous ubiquinol prevents protein modification accompanying lipid peroxidation in beef heart submitochondrial particles. Free Radic Biol Med. (1995)
- ^ Forsmark-Andrée P, et al. Oxidative modification of nicotinamide nucleotide transhydrogenase in submitochondrial particles: effect of endogenous ubiquinol. Arch Biochem Biophys. (1996)
- ^ Coenzyme Q10 enrichment decreases oxidative DNA damage in human lymphocytes.
- ^ Lewis KN, et al. Nrf2, a guardian of healthspan and gatekeeper of species longevity. Integr Comp Biol. (2010)
- ^ Reuland DJ, et al. Upregulation of phase II enzymes through phytochemical activation of Nrf2 protects cardiomyocytes against oxidant stress. Free Radic Biol Med. (2013)
- ^ Hybertson BM, et al. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Aspects Med. (2011)
- ^ a b Choi HK, et al. Inhibition of liver fibrosis by solubilized coenzyme Q10: Role of Nrf2 activation in inhibiting transforming growth factor-beta1 expression. Toxicol Appl Pharmacol. (2009)
- ^ a b Wada H, et al. Redox status of coenzyme Q10 is associated with chronological age. J Am Geriatr Soc. (2007)
- ^ Sohal RS. Hydrogen peroxide production by mitochondria may be a biomarker of aging. Mech Ageing Dev. (1991)
- ^ HARMAN D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. (1956)
- ^ Fuchs J, et al. Electron paramagnetic resonance (EPR) imaging in skin: biophysical and biochemical microscopy. J Invest Dermatol. (1992)
- ^ A survey of reactive oxygen species and their role in dermatology.
- ^ Sun Y, Oberley LW. Redox regulation of transcriptional activators. Free Radic Biol Med. (1996)
- ^ Cerutti PA, Trump BF. Inflammation and oxidative stress in carcinogenesis. Cancer Cells. (1991)
- ^ Suzuki YJ, Forman HJ, Sevanian A. Oxidants as stimulators of signal transduction. Free Radic Biol Med. (1997)
- ^ Shindo Y, et al. Enzymic and non-enzymic antioxidants in epidermis and dermis of human skin. J Invest Dermatol. (1994)
- ^ Podda M, et al. UV-irradiation depletes antioxidants and causes oxidative damage in a model of human skin. Free Radic Biol Med. (1998)
- ^ Hoppe U, et al. Coenzyme Q10, a cutaneous antioxidant and energizer. Biofactors. (1999)
- ^ del Hoyo P, et al. Oxidative stress in skin fibroblasts cultures from patients with Parkinson’s disease. BMC Neurol. (2010)
- ^ del Hoyo P, et al. Oxidative stress in skin fibroblasts cultures of patients with Huntington’s disease. Neurochem Res. (2006)
- ^ a b c Cordero MD, et al. Mitochondrial dysfunction in skin biopsies and blood mononuclear cells from two cases of fibromyalgia patients. Clin Biochem. (2010)
- ^ a b Prahl S, et al. Aging skin is functionally anaerobic: importance of coenzyme Q10 for anti aging skin care. Biofactors. (2008)
- ^ a b Blatt T, Littarru GP. Biochemical rationale and experimental data on the antiaging properties of CoQ(10) at skin level. Biofactors. (2011)
- ^ a b Zhang M, et al. Coenzyme Q(10) enhances dermal elastin expression, inhibits IL-1α production and melanin synthesis in vitro. Int J Cosmet Sci. (2012)
- ^ Inui M, et al. Mechanisms of inhibitory effects of CoQ10 on UVB-induced wrinkle formation in vitro and in vivo. Biofactors. (2008)
- ^ López LC, et al. Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects. PLoS One. (2010)
- ^ Choi BS, et al. Effect of coenzyme Q10 on cutaneous healing in skin-incised mice. Arch Pharm Res. (2009)
- ^ a b Cordero MD, et al. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther. (2010)
- ^ a b Cordero MD, et al. Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q₁₀ effect on clinical improvement. PLoS One. (2012)
- ^ Cordero MD, et al. Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia. Clin Biochem. (2009)
- ^ Cordero MD, et al. Coenzyme Q10 in salivary cells correlate with blood cells in Fibromyalgia: improvement in clinical and biochemical parameter after oral treatment. Clin Biochem. (2012)
- ^ Cordero MD, et al. Oxidative stress and mitochondrial dysfunction in fibromyalgia. Neuro Endocrinol Lett. (2010)
- ^ Cordero MD, et al. Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathologic alterations in blood mononuclear cells in a fibromyalgia patient. Nutrition. (2012)
- ^ Cordero MD, et al. Coenzyme Q(10): a novel therapeutic approach for Fibromyalgia? case series with 5 patients. Mitochondrion. (2011)
- ^ a b Cordero MD, et al. Can Coenzyme Q10 improve clinical and molecular parameter in Fibromyalgia. Antioxid Redox Signal. (2013)
- ^ a b Miyamae T, et al. Increased oxidative stress and coenzyme Q10 deficiency in juvenile fibromyalgia: amelioration of hypercholesterolemia and fatigue by ubiquinol-10 supplementation. Redox Rep. (2013)
- ^ Goldstone AP. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab. (2004)
- ^ a b Miller JL, et al. Carnitine and coenzyme Q10 levels in individuals with Prader-Willi syndrome. Am J Med Genet A. (2011)
- ^ Eiholzer U, et al. Developmental profiles in young children with Prader-Labhart-Willi syndrome: effects of weight and therapy with growth hormone or coenzyme Q10. Am J Med Genet A. (2008)
- ^ Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. Altern Med Rev. (2000)
- ^ Bentler SE, Hartz AJ, Kuhn EM. Prospective observational study of treatments for unexplained chronic fatigue. J Clin Psychiatry. (2005)
- ^ Maes M, et al. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett. (2009)
- ^ Mikirova N, Casciari J, Hunninghake R. The assessment of the energy metabolism in patients with chronic fatigue syndrome by serum fluorescence emission. Altern Ther Health Med. (2012)
- ^ Mancini A, et al. Seminal antioxidants in humans: preoperative and postoperative evaluation of coenzyme Q10 in varicocele patients. Horm Metab Res. (2005)
- ^ Balercia G, et al. Coenzyme Q10 and male infertility. J Endocrinol Invest. (2009)
- ^ a b Mancini A, Balercia G. Coenzyme Q(10) in male infertility: physiopathology and therapy. Biofactors. (2011)
- ^ Balercia G, et al. Total oxyradical scavenging capacity toward different reactive oxygen species in seminal plasma and sperm cells. Clin Chem Lab Med. (2003)
- ^ Aitken RJ, Clarkson JS, Fishel S. Generation of reactive oxygen species, lipid peroxidation, and human sperm function. Biol Reprod. (1989)
- ^ Aitken RJ, et al. New insights into sperm physiology and pathology. Handb Exp Pharmacol. (2010)
- ^ Desai N, et al. Free radical theory of aging: implications in male infertility. Urology. (2010)
- ^ Fawcett DW. The mammalian spermatozoon. Dev Biol. (1975)
- ^ Kalén A, et al. Nonaprenyl-4-hydroxybenzoate transferase, an enzyme involved in ubiquinone biosynthesis, in the endoplasmic reticulum-Golgi system of rat liver. J Biol Chem. (1990)
- ^ Aitken RJ, et al. Analysis of sperm movement in relation to the oxidative stress created by leukocytes in washed sperm preparations and seminal plasma. Hum Reprod. (1995)
- ^ Ford WC, Whittington K. Antioxidant treatment for male subfertility: a promise that remains unfulfilled. Hum Reprod. (1998)
- ^ Johnson L, Varner DD. Effect of daily spermatozoan production but not age on transit time of spermatozoa through the human epididymis. Biol Reprod. (1988)
- ^ Wolff H, et al. Leukocytospermia is associated with poor semen quality. Fertil Steril. (1990)
- ^ a b Mancini A, et al. Coenzyme Q10: another biochemical alteration linked to infertility in varicocele patients. Metabolism. (2003)
- ^ Mancini A, et al. Effects of testosterone on antioxidant systems in male secondary hypogonadism. J Androl. (2008)
- ^ Mancini A, et al. Evaluation of antioxidant systems in pituitary-adrenal axis diseases. Pituitary. (2010)
- ^ a b c d Balercia G, et al. Coenzyme Q(10) supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertil Steril. (2004)
- ^ a b Balercia G, et al. Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertil Steril. (2009)
- ^ Angelitti AG, et al. Coenzyme Q: potentially useful index of bioenergetic and oxidative status of spermatozoa. Clin Chem. (1995)
- ^ Mancini A, et al. Relationship between sperm cell ubiquinone and seminal parameters in subjects with and without varicocele. Andrologia. (1998)
- ^ Naughton CK, Nangia AK, Agarwal A. Pathophysiology of varicoceles in male infertility. Hum Reprod Update. (2001)
- ^ a b Lewin A, Lavon H. The effect of coenzyme Q10 on sperm motility and function. Mol Aspects Med. (1997)
- ^ a b Safarinejad MR. Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. J Urol. (2009)
- ^ Pryor J, et al. Peyronie’s disease. J Sex Med. (2004)
- ^ Lindsay MB, et al. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol. (1991)
- ^ a b Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie’s disease: a double-blind, placebo-controlled randomized study. Int J Impot Res. (2010)
- ^ Tarnopolsky MA. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv Drug Deliv Rev. (2008)
- ^ Bertelli A, Ronca G. Carnitine and coenzyme Q10: biochemical properties and functions, synergism and complementary action. Int J Tissue React. (1990)
- ^ Shojaei M, et al. Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy. Iran J Kidney Dis. (2011)
- ^ Duguez S, et al. Mitochondrial biogenesis during skeletal muscle regeneration. Am J Physiol Endocrinol Metab. (2002)
- ^ Wu Z, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. (1999)
- ^ Turchanowa L, et al. Influence of physical exercise on polyamine synthesis in the rat skeletal muscle. Eur J Clin Invest. (2000)
- ^ Lee NK, MacLean HE. Polyamines, androgens, and skeletal muscle hypertrophy. J Cell Physiol. (2011)
- ^ Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem. (2007)
- ^ Jeng KC, et al. Effect of microbial fermentation on content of statin, GABA, and polyphenols in Pu-Erh tea. J Agric Food Chem. (2007)
- ^ Keith M, et al. Coenzyme Q10 in patients undergoing CABG: Effect of statins and nutritional supplementation. Nutr Metab Cardiovasc Dis. (2008)
- ^ Ghirlanda G, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. (1993)
- ^ Wynn RL. The effects of CoQ10 supplements on patients taking statin drugs. Gen Dent. (2010)
- ^ Nielsen ML, Pareek M, Henriksen JE. Reduced synthesis of coenzyme Q10 may cause statin related myopathy. Ugeskr Laeger. (2011)
- ^ Silver MA, et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. (2004)
- ^ Sikka P, et al. Statin intolerance: now a solved problem. J Postgrad Med. (2011)
- ^ Harper CR, Jacobson TA. Evidence-based management of statin myopathy. Curr Atheroscler Rep. (2010)
- ^ Wyman M, Leonard M, Morledge T. Coenzyme Q10: a therapy for hypertension and statin-induced myalgia. Cleve Clin J Med. (2010)
- ^ Toyama K, et al. Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease. Atherosclerosis. (2011)
- ^ Dahan A, Amidon GL. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res. (2009)
- ^ Honda Y, et al. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. (2004)
- ^ Grapefruit juice enhance the uptake of coenzyme Q10 in the human intestinal cell-line Caco-2.
- ^ Belcaro G, et al. Investigation of Pycnogenol® in combination with coenzymeQ10 in heart failure patients (NYHA II/III). Panminerva Med. (2010)
- ^ Hidaka T, et al. Safety assessment of coenzyme Q10 (CoQ10). Biofactors. (2008)
- ^ Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. (2007)
- ^ Rosenfeldt FL, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. (2007)
- ^ Rosenfeldt F, et al. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors. (2003)
- ^ Ferrante KL, et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology. (2005)
- ^ Shults CW, et al. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson’s disease. Exp Neurol. (2004)
- ^ Shults CW, Haas R. Clinical trials of coenzyme Q10 in neurological disorders. Biofactors. (2005)
- ^ Ikematsu H, et al. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial. Regul Toxicol Pharmacol. (2006)
- ^ Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.
- Yubero-Serrano EM, et al. Postprandial antioxidant effect of the Mediterranean diet supplemented with coenzyme Q10 in elderly men and women. Age (Dordr). (2011)
- Teran E, et al. Coenzyme Q10 supplementation during pregnancy reduces the risk of pre-eclampsia. Int J Gynaecol Obstet. (2009)
- Dai YL, et al. Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial. Atherosclerosis. (2011)
- Fumagalli S, et al. Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study. Clin Cardiol. (2011)
- Shah SA, et al. Electrocardiographic and hemodynamic effects of coenzyme Q10 in healthy individuals: a double-blind, randomized controlled trial. Ann Pharmacother. (2007)
- Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J. (2001)
- Müller T, et al. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neurosci Lett. (2003)
- Gökbel H, et al. Effects of coenzyme Q10 supplementation on plasma adiponectin, interleukin-6, and tumor necrosis factor-alpha levels in men. J Med Food. (2010)
- Nadjarzadeh A, et al. Coenzyme Q10 improves seminal oxidative defense but does not affect on semen parameters in idiopathic oligoasthenoteratozoospermia: a randomized double-blind, placebo controlled trial. J Endocrinol Invest. (2011)
- Yubero-Serrano EM, et al. Mediterranean Diet Supplemented With Coenzyme Q10 Modifies the Expression of Proinflammatory and Endoplasmic Reticulum Stress-Related Genes in Elderly Men and Women. J Gerontol A Biol Sci Med Sci. (2011)
- Liao P, et al. Effects of coenzyme Q10 supplementation on liver mitochondrial function and aerobic capacity in adolescent athletes. Zhongguo Ying Yong Sheng Li Xue Za Zhi. (2007)
- Zhang P, et al. Treatment of coenzyme Q10 for 24 weeks improves lipid and glycemic profile in dyslipidemic individuals. J Clin Lipidol. (2018)
- Dahri M, et al. Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers. Nutr Neurosci. (2018)
- Shoeibi A, et al. Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial. Acta Neurol Belg. (2017)
- Mehrpooya M, et al. Evaluating the Effect of Coenzyme Q10 Augmentation on Treatment of Bipolar Depression: A Double-Blind Controlled Clinical Trial. J Clin Psychopharmacol. (2018)
- Nadjarzadeh A, et al. Effect of Coenzyme Q10 supplementation on antioxidant enzymes activity and oxidative stress of seminal plasma: a double-blind randomised clinical trial. Andrologia. (2014)
- Sawaddiruk P, et al. Coenzyme Q10 supplementation alleviates pain in pregabalin-treated fibromyalgia patients via reducing brain activity and mitochondrial dysfunction. Free Radic Res. (2019)
- Parohan M, et al. The synergistic effects of nano-curcumin and coenzyme Q10 supplementation in migraine prophylaxis: a randomized, placebo-controlled, double-blind trial. Nutr Neurosci. (2019)
- Izadi A, et al. Hormonal and Metabolic Effects of Coenzyme Q10 and/or Vitamin E in Patients With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. (2019)
- Mousavinejad E, et al. Coenzyme Q10 supplementation reduces oxidative stress and decreases antioxidant enzyme activity in children with autism spectrum disorders. Psychiatry Res. (2018)
- Sanoobar M, et al. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci. (2015)
- Sanoobar M, et al. Coenzyme Q10 as a treatment for fatigue and depression in multiple sclerosis patients: A double blind randomized clinical trial. Nutr Neurosci. (2016)
- Gholami M, et al. Effects of coenzyme Q10 supplementation on serum values of adiponectin, leptin, 8-isoprostane and malondialdehyde in women with type 2 diabetes. Gynecol Endocrinol. (2018)
- Jahangard L, et al. Influence of adjuvant Coenzyme Q10 on inflammatory and oxidative stress biomarkers in patients with bipolar disorders during the depressive episode. Mol Biol Rep. (2019)
- Fallah M, et al. Clinical trial of the effects of coenzyme Q10 supplementation on glycemic control and markers of lipid profiles in diabetic hemodialysis patients. Int Urol Nephrol. (2018)
- Mohseni M, et al. Beneficial Effects of Coenzyme Q10 Supplementation on Lipid Profile and Intereukin-6 and Intercellular Adhesion Molecule-1 Reduction, Preliminary Results of a Double-blind Trial in Acute Myocardial Infarction. Int J Prev Med. (2015)
- Serag H, El Wakeel L, Adly A. Coenzyme Q10 administration has no effect on sICAM-1 and metabolic parameters of pediatrics with type 1 diabetes mellitus. Int J Vitam Nutr Res. (2020)
- Žmitek K, et al. The effect of dietary intake of coenzyme Q10 on skin parameters and condition: Results of a randomised, placebo-controlled, double-blind study. Biofactors. (2017)
- Martin JK, et al. Phospholipase A2 as a probe of phospholipid distribution in erythrocyte membranes. Factors influencing the apparent specificity of the reaction. Biochemistry. (1975)
- Mirhashemi SM, et al. The effects of coenzyme Q10 supplementation on cardiometabolic markers in overweight type 2 diabetic patients with stable myocardial infarction: A randomized, double-blind, placebo-controlled trial. ARYA Atheroscler. (2016)